Details
Stereochemistry | ACHIRAL |
Molecular Formula | 2C12H11N2O3.Mg |
Molecular Weight | 486.7597 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 0 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Mg++].CCC1(C(=O)NC(=O)[N-]C1=O)C2=CC=CC=C2.CCC3(C(=O)NC(=O)[N-]C3=O)C4=CC=CC=C4
InChI
InChIKey=LJVBIGYQTUCCSB-UHFFFAOYSA-L
InChI=1S/2C12H12N2O3.Mg/c2*1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16;/h2*3-7H,2H2,1H3,(H2,13,14,15,16,17);/q;;+2/p-2
Molecular Formula | C12H12N2O3 |
Molecular Weight | 232.2353 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Mg |
Molecular Weight | 24.305 |
Charge | 2 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.drugs.com/monograph/phenobarbital.htmlCurator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB01174
Sources: https://www.drugs.com/monograph/phenobarbital.html
Curator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB01174
Phenobarbital is a barbiturate derivative used to treat insomnia and anxiety, seizures, hyperbilirubinemia in neonates and cholestasis. Phenobarbital promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2093872 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16981722 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | LUMINAL Approved UseShort-term treatment of insomnia. However, generally not used orally as a hypnotic because several hours are required to achieve maximal effectsa and barbiturates have decreased effectiveness for sleep induction and maintenance after 2 weeks. |
|||
Primary | LUMINAL Approved UseRelief of anxiety, tension, and apprehension. However, barbiturates used infrequently for routine sedation, since there are few clinical situations in which oral barbiturates provide a safety or efficacy advantage over nonbarbiturate sedatives/hypnotics. |
|||
Primary | LUMINAL Approved UseManagement of tonic-clonic seizures and partial seizures; used alone (particularly in infants and young children) or, more commonly, in combination with phenytoin or other anticonvulsants. |
|||
Preventing | LUMINAL Approved UsePrevention of febrile seizures in infants and young children. |
|||
Primary | LUMINAL Approved UseSecond-line agent in the termination of status epilepticus; may be useful to prevent seizure recurrence after seizures are initially terminated with other anticonvulsants (e.g., diazepam, phenytoin) or for termination of status epilepticus that does not respond to initial therapy with other anticonvulsants. Usefulness of parenteral phenobarbital in terminating acute seizure episodes is limited by its slow onset of action |
|||
Preventing | LUMINAL Approved UseProphylactic management of epilepsy. |
|||
Primary | LUMINAL Approved UsePrevention and treatment of hyperbilirubinemia in neonates |
|||
Primary | LUMINAL Approved UseHas been used to reduce bilirubin concentrations in patients with congenital nonhemolytic unconjugated hyperbilirubinemia or chronic intrahepatic cholestasis. Has been used in the management of hyperlipemia associated with intrahepatic and extrahepatic cholestasis |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/monograph/phenobarbital.html
Phenobarbital is administered orally or by IM or slow IV injection. For treatment of anxiety, phenobarbital is administered orally 6 mg/kg daily or 180 mg/m2 daily, in 3 equally divided doses. For treatment of seizure disorders, the drug is administered orally 15–50 mg 2 or 3 times daily. Alternatively, 3–5 mg/kg or 125 mg/m2 daily; IV or IM 4–6 mg/kg daily for 7–10 days to reach therapeutic blood concentrations; alternatively, 10–15 mg/kg daily.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16981722
Potentiation of the GABAA by phenobarbital was evaluated in HEK293 cells expressing recombinant rat GABAA receptors. Currents were recorded using the cell-flow technique and corrected for receptor desensitization. Co-application of phenobarbital with 300uM GABA lead to 20-30 amplification of chloride currents with EC50 of 100-200 uM
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:18:05 GMT 2023
by
admin
on
Fri Dec 15 15:18:05 GMT 2023
|
Record UNII |
RSK622Z0BN
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
7645-05-8
Created by
admin on Fri Dec 15 15:18:05 GMT 2023 , Edited by admin on Fri Dec 15 15:18:05 GMT 2023
|
SUPERSEDED | |||
|
SUB127889
Created by
admin on Fri Dec 15 15:18:05 GMT 2023 , Edited by admin on Fri Dec 15 15:18:05 GMT 2023
|
PRIMARY | |||
|
56842055
Created by
admin on Fri Dec 15 15:18:05 GMT 2023 , Edited by admin on Fri Dec 15 15:18:05 GMT 2023
|
PRIMARY | |||
|
100000153682
Created by
admin on Fri Dec 15 15:18:05 GMT 2023 , Edited by admin on Fri Dec 15 15:18:05 GMT 2023
|
PRIMARY | |||
|
RSK622Z0BN
Created by
admin on Fri Dec 15 15:18:05 GMT 2023 , Edited by admin on Fri Dec 15 15:18:05 GMT 2023
|
PRIMARY | |||
|
17140-94-2
Created by
admin on Fri Dec 15 15:18:05 GMT 2023 , Edited by admin on Fri Dec 15 15:18:05 GMT 2023
|
PRIMARY | |||
|
241-206-2
Created by
admin on Fri Dec 15 15:18:05 GMT 2023 , Edited by admin on Fri Dec 15 15:18:05 GMT 2023
|
PRIMARY | |||
|
DTXSID40937987
Created by
admin on Fri Dec 15 15:18:05 GMT 2023 , Edited by admin on Fri Dec 15 15:18:05 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |